Actelion mainly integrates additional innovation into its pipeline through in-licensing, but does not exclude acquisitions should the opportunity arise.

Axovan
Actelion acquired privately-owned Axovan AG in September 2003, integrating into its pipeline clazosentan, an intravenous endothelin receptor antagonist.

CoTherix Inc.
Actelion completed the acquisition of CoTherix Inc. in March 2007, thereby strengthening its PAH franchise by adding Ventavis® to its product offerings in the United States.